NERVGEN PHARMA CORP (NGEN.CA) Stock Analyst Ratings
Canada - TSX Venture Exchange - TSX-V:NGEN - CA64082X2032 - Common Stock
8.08 CAD
+0.26 (+3.32%)
ChartMill assigns a Buy % Consensus number of 80% to NGEN.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.75. This target is -4.06% below the current price.
NGEN.CA was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about NGEN.CA.
In the previous month the buy percentage consensus was at a similar level.
NGEN.CA was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
NERVGEN PHARMA CORP / NGEN.CA FAQ
What is the average price target for NERVGEN PHARMA CORP (NGEN.CA) stock?
8 analysts have analysed NGEN.CA and the average price target is 7.75 CAD. This implies a price decrease of -4.06% is expected in the next year compared to the current price of 8.08.
What is the consensus rating for NERVGEN PHARMA CORP (NGEN.CA) stock?
The consensus rating for NERVGEN PHARMA CORP (NGEN.CA) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed NERVGEN PHARMA CORP (NGEN.CA)?
The number of analysts covering NERVGEN PHARMA CORP (NGEN.CA) is 8.